You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Additional costs related to formulation, chronic tox and general development of PTI-125
SBC: PAIN THERAPEUTICS, INC. Topic: NIAProject Summary Abstract PTIis a novel small molecule AD therapeutic candidate with a novel target and mechanism of actionPTIbinds and reverses an altered conformation of the scaffolding protein filamin AFLNAto prevent Aandapos s tight binding to and toxic signaling via thenicotinic acetylcholine receptornAChRas well as Aandapos s aberrant activation of toll like receptorTLRHenceby restoring FLNAa ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
MicroRNA-based Radiation Biodosimeter (MiRAD) Phase II
SBC: CHROMOLOGIC LLC Topic: NIAIDAbstract In response to PA-15-065, the broad long-term goal of this project is to develop a portable radiation biodosimeter to be used at the point-of-care (POC) for assessing precise radiation exposure and susceptibility for acute radiation syndrome (ARS) within the first 7 days of exposure starting with ~250 µL of blood collected from a finger stick and a turnaround time (TAT) of less than 40 m ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis
SBC: Epigen Biosciences, Inc. Topic: 400SummaryThe ultimate goal of our project is to develop novel therapeutics effective in chronic kidney diseases, such as diabetic nephropathy (DN), that normally develop fibrosis, lead to end stage renal disease and require renal replacement therapy. DN is a complication of diabetes and is characterized by thickening of the glomerular basement membrane and mesangial expansion, with progression into ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
sHLA Protein Chip
SBC: GENOMICS USA, INC. Topic: NIAIDAbstract: “sHLA Protein Chip” The class I [A, B, C] and class II HLA proteins [DRB1, DQ, DP] comprise the heart of the inducible human immune system. For organ, marrow and stem cell transplantation, the development of serum-born antibodies against one or more of those many HLA proteins comprises the best and earliest test for transplant rejection. Because of the enormous medical importance of ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain
SBC: AFASCI, INC. Topic: NINDS7. PROJECT SUMMARY Neuropathic pain remains a poorly managed medical condition affecting more than 1.5 billion people worldwide. Over 20 million people suffered from diabetic neuropathy and neuropathic pain in the US alone in 2015. The current standard of care is insufficient. Topical applications and systemic treatment with existing analgesics, including opioids, leave millions suffering. More th ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Phase IIB: Exploratory Clinical trials for The V Needle
SBC: HEMOTEK Topic: 400Hemodialysis (HD) is generally perceived as a safe, benign, procedure. But if venous needle dislodgement (VND) occurs during dialysis and the machine fails to detect it, within minutes the blood loss can be catastrophic, and even fatal. It is estimated that 400 dialysis patients suffer a dislodgement episode every week in the US. [3] In a Phase I/Phase II SBIR partnership with our clinical and med ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Prospective evaluation of a surgical solution for breast cancer-associated lymphedema
SBC: Fibralign Corporation Topic: 102Project Summary/Abstract Prospective evaluation of a surgical solution for breast cancer-associated lymphedema The proposed project will complete remaining key research and technology requirements that are needed to commercialize a ground-breaking interventional device for treating secondary lymphedema -- a chronic and debilitating disease that currently has no cure and impacts an estimated 15-30% ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Peripherally-restricted and long-acting kappa-opioid receptor (LA-KOR) agonists for pain
SBC: PEPTIDE LOGIC LLC Topic: NIDAPROJECT SUMMARYPain management poses significant clinical challenges due to its very high prevalencethe diversity of patients and underlying mechanismsand the lack of safe and effective treatment optionsApproximatelymillion Americans experience acute post operative painwhereas aboutmillion US adults suffer from chronic painOpioids remain the most effective class of analgesics for moderate to sever ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD
SBC: VIROGENICS, INC. Topic: RAbstractThere are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos;s disease (AD). Age is by far the greatest risk factor for AD, and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD. Therefore, a drug that could reduce neuroinflammation and at the ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Development of RNAi-based inhibitors against the Hepatitis Delta Virus
SBC: Somagenics, Inc. Topic: NIAIDAbstract Hepatitis D virus (HDV) infection is the most severe type of viral hepatitis, often causing accelerated liver damage that leads to end-stage liver disease. About 15–20 million individuals are infected by HDV worldwide. The absence of an effective treatment for acute forms of the disease and the limited efficacy of current treatments for the chronic infection justify novel strategies tow ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health